hotspot -WSS

hotspot

author：fashion 2025-08-10 11:42:29 - browse：3474

US Capitol - SOTU — Lawmakers in Congress have decided to punt efforts to reform how PBMs operate. BRENDAN SMIALOWSKI/AFP/Getty Images

WASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate in an upcoming package to fund the federal government, 11 lobbyists and sources following the talks told STAT.

It’s a missed opportunity to pass one of the health care priorities that has attracted the most bipartisan interest and activity this Congress, though lawmakers could revive the negotiations on the issues in the future.

Reforming how pharmacy benefit managers operate has been a top lobbying priority for the pharmaceutical industry since Democrats passed a major package aimed at lowering the costs of medicines in 2022. Pharma and PBMs have taken up a very public battle on the airwaves.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： FDA approves world's first CRISPR

entertainment

focus

WSS

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Roche acquires Telavant from Roivant, adding experimental IBD treatment

UnitedHealth, Optum discontinue NaviHealth name

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Study on Amgen’s bispecific immunotherapy produces positive data

Supreme Court wrestles with OxyContin maker's bankruptcy deal

focus

hotspot

Wikipedia

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA needs staff influx to meet gene therapy needs, Marks says

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Results on Novartis prostate cancer therapy could expand its use

Sports medicine is finally prioritizing gender equality

AI models in health care face new federal disclosure requirements

United colonoscopy coverage change 'may cost lives,' doctors say

CMS should re

DIEP, the 'gold standard' of breast reconstruction, is under threat

Chemotherapy shortages won’t get better under Biden’s latest plan

hotspot

UnitedHealth, Optum discontinue NaviHealth name

Study on Amgen’s bispecific immunotherapy produces positive data

Roche acquires Telavant from Roivant, adding experimental IBD treatment

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

CZI to create biohub to build anti

After sickle

entertainment

Wikipedia

focus

Wikipedia